An exploratory study-level meta-analysis assessing the impact of early tumour shrinkage on overall survival in patients with RAS wild-type metastat...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter F. Rivera
Citation Annals of Oncology (2016) 27 (2): 102-117. 10.1093/annonc/mdw200
Authors F. Rivera1, M. Karthaus2, M. Valladares-Ayerbes3, J. Gallego4, R. Koukakis5, G. Demonty6, J.-. Douillard7
  • 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, /
  • 2Städtisches Klinikum München, Klinikum Neuperlach, Munich, Germany, /
  • 3Virgen del Rocio Hospital, IBIS Institute for Biomedicina of Seville, Seville, Spain, /
  • 4Hospital General Universitario de Elche, Elche, Spain, /
  • 5Amgen Ltd, Uxbridge, United Kingdom, /
  • 6Amgen (Europe) GmbH, Zug, Switzerland, /
  • 7Institut de Cancérologie de l'Ouest (ICO) René Gauducheau, St Herblain, France, /


Achieving tumour shrinkage is an important treatment goal in patients with metastatic colorectal cancer (mCRC) as it may increase the chance of surgical resection and provide relief of tumour-related symptoms. Early tumour shrinkage (ETS) can provide an early indication of sensitivity to treatment and has also been associated with improved overall survival (OS). Here we report results of a meta-analysis analysing the impact of ETS on OS in patients with RAS wild-type (WT) mCRC receiving first-line treatment in three randomised panitumumab trials.